vs
Avantor, Inc.（AVTR）与沃特世（WAT）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是沃特世的1.8倍（$1.7B vs $932.4M）。沃特世净利率更高（24.2% vs 3.1%，领先21.0%）。沃特世同比增速更快（6.8% vs -1.4%）。过去两年沃特世的营收复合增速更高（21.0% vs -0.5%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
沃特世是总部位于美国马萨诸塞州米尔福德的企业，面向生命科学、材料、食品等行业，提供色谱、质谱、实验室信息学、流变测量领域所用的分析仪器及配套软件，为各领域的检测、研发等工作提供可靠技术支持。
AVTR vs WAT — 直观对比
营收规模更大
AVTR
是对方的1.8倍
$932.4M
营收增速更快
WAT
高出8.2%
-1.4%
净利率更高
WAT
高出21.0%
3.1%
两年增速更快
WAT
近两年复合增速
-0.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $932.4M |
| 净利润 | $52.4M | $225.2M |
| 毛利率 | 31.5% | 61.1% |
| 营业利润率 | 7.6% | 29.0% |
| 净利率 | 3.1% | 24.2% |
| 营收同比 | -1.4% | 6.8% |
| 净利润同比 | -89.5% | -2.7% |
| 每股收益（稀释后） | $0.08 | $3.76 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRWAT
| Q4 25 | $1.7B | $932.4M | ||
| Q3 25 | $1.6B | $799.9M | ||
| Q2 25 | $1.7B | $771.3M | ||
| Q1 25 | $1.6B | $661.7M | ||
| Q4 24 | $1.7B | $872.7M | ||
| Q3 24 | $1.7B | $740.3M | ||
| Q2 24 | $1.7B | $708.5M | ||
| Q1 24 | $1.7B | $636.8M |
净利润AVTRWAT
| Q4 25 | $52.4M | $225.2M | ||
| Q3 25 | $-711.8M | $148.9M | ||
| Q2 25 | $64.7M | $147.1M | ||
| Q1 25 | $64.5M | $121.4M | ||
| Q4 24 | $500.4M | $231.4M | ||
| Q3 24 | $57.8M | $161.5M | ||
| Q2 24 | $92.9M | $142.7M | ||
| Q1 24 | $60.4M | $102.2M |
毛利率AVTRWAT
| Q4 25 | 31.5% | 61.1% | ||
| Q3 25 | 32.4% | 59.0% | ||
| Q2 25 | 32.9% | 58.3% | ||
| Q1 25 | 33.8% | 58.2% | ||
| Q4 24 | 33.4% | 60.1% | ||
| Q3 24 | 32.9% | 59.3% | ||
| Q2 24 | 34.1% | 59.3% | ||
| Q1 24 | 34.0% | 58.9% |
营业利润率AVTRWAT
| Q4 25 | 7.6% | 29.0% | ||
| Q3 25 | -40.0% | 24.0% | ||
| Q2 25 | 7.7% | 24.4% | ||
| Q1 25 | 9.3% | 22.9% | ||
| Q4 24 | 37.8% | 33.5% | ||
| Q3 24 | 7.3% | 28.5% | ||
| Q2 24 | 10.3% | 26.7% | ||
| Q1 24 | 8.7% | 21.0% |
净利率AVTRWAT
| Q4 25 | 3.1% | 24.2% | ||
| Q3 25 | -43.8% | 18.6% | ||
| Q2 25 | 3.8% | 19.1% | ||
| Q1 25 | 4.1% | 18.3% | ||
| Q4 24 | 29.7% | 26.5% | ||
| Q3 24 | 3.4% | 21.8% | ||
| Q2 24 | 5.5% | 20.1% | ||
| Q1 24 | 3.6% | 16.0% |
每股收益（稀释后）AVTRWAT
| Q4 25 | $0.08 | $3.76 | ||
| Q3 25 | $-1.04 | $2.50 | ||
| Q2 25 | $0.09 | $2.47 | ||
| Q1 25 | $0.09 | $2.03 | ||
| Q4 24 | $0.73 | $3.88 | ||
| Q3 24 | $0.08 | $2.71 | ||
| Q2 24 | $0.14 | $2.40 | ||
| Q1 24 | $0.09 | $1.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | $587.8M |
| 总债务越低越好 | $3.9B | $1.4B |
| 股东权益账面价值 | $5.6B | $2.6B |
| 总资产 | $11.8B | $5.1B |
| 负债/权益比越低杠杆越低 | 0.71× | 0.55× |
8季度趋势，按日历期对齐
现金及短期投资AVTRWAT
| Q4 25 | $365.4M | $587.8M | ||
| Q3 25 | $251.9M | $459.1M | ||
| Q2 25 | $449.4M | $367.2M | ||
| Q1 25 | $315.7M | $382.9M | ||
| Q4 24 | $261.9M | $325.4M | ||
| Q3 24 | $285.3M | $331.5M | ||
| Q2 24 | $272.6M | $327.4M | ||
| Q1 24 | $234.9M | $338.2M |
总债务AVTRWAT
| Q4 25 | $3.9B | $1.4B | ||
| Q3 25 | $3.9B | — | ||
| Q2 25 | $4.2B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | $1.6B | ||
| Q3 24 | $4.9B | — | ||
| Q2 24 | $5.1B | — | ||
| Q1 24 | $5.3B | — |
股东权益AVTRWAT
| Q4 25 | $5.6B | $2.6B | ||
| Q3 25 | $5.6B | $2.3B | ||
| Q2 25 | $6.3B | $2.2B | ||
| Q1 25 | $6.1B | $2.0B | ||
| Q4 24 | $6.0B | $1.8B | ||
| Q3 24 | $5.6B | $1.6B | ||
| Q2 24 | $5.4B | $1.4B | ||
| Q1 24 | $5.3B | $1.3B |
总资产AVTRWAT
| Q4 25 | $11.8B | $5.1B | ||
| Q3 25 | $11.7B | $4.9B | ||
| Q2 25 | $12.8B | $4.7B | ||
| Q1 25 | $12.3B | $4.6B | ||
| Q4 24 | $12.1B | $4.6B | ||
| Q3 24 | $12.8B | $4.5B | ||
| Q2 24 | $12.7B | $4.4B | ||
| Q1 24 | $12.8B | $4.5B |
负债/权益比AVTRWAT
| Q4 25 | 0.71× | 0.55× | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.68× | 0.89× | ||
| Q3 24 | 0.89× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | 1.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | $164.6M |
| 自由现金流经营现金流 - 资本支出 | $117.2M | — |
| 自由现金流率自由现金流/营收 | 7.0% | — |
| 资本支出强度资本支出/营收 | 2.1% | — |
| 现金转化率经营现金流/净利润 | 2.91× | 0.73× |
| 过去12个月自由现金流最近4个季度 | $495.0M | — |
8季度趋势，按日历期对齐
经营现金流AVTRWAT
| Q4 25 | $152.7M | $164.6M | ||
| Q3 25 | $207.4M | $187.3M | ||
| Q2 25 | $154.4M | $41.1M | ||
| Q1 25 | $109.3M | $259.6M | ||
| Q4 24 | $173.3M | $240.1M | ||
| Q3 24 | $244.8M | $204.6M | ||
| Q2 24 | $281.1M | $54.5M | ||
| Q1 24 | $141.6M | $262.9M |
自由现金流AVTRWAT
| Q4 25 | $117.2M | — | ||
| Q3 25 | $171.7M | — | ||
| Q2 25 | $124.8M | — | ||
| Q1 25 | $81.3M | — | ||
| Q4 24 | $145.8M | — | ||
| Q3 24 | $204.0M | — | ||
| Q2 24 | $235.3M | — | ||
| Q1 24 | $106.9M | — |
自由现金流率AVTRWAT
| Q4 25 | 7.0% | — | ||
| Q3 25 | 10.6% | — | ||
| Q2 25 | 7.4% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 8.6% | — | ||
| Q3 24 | 11.9% | — | ||
| Q2 24 | 13.8% | — | ||
| Q1 24 | 6.4% | — |
资本支出强度AVTRWAT
| Q4 25 | 2.1% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 2.1% | — |
现金转化率AVTRWAT
| Q4 25 | 2.91× | 0.73× | ||
| Q3 25 | — | 1.26× | ||
| Q2 25 | 2.39× | 0.28× | ||
| Q1 25 | 1.69× | 2.14× | ||
| Q4 24 | 0.35× | 1.04× | ||
| Q3 24 | 4.24× | 1.27× | ||
| Q2 24 | 3.03× | 0.38× | ||
| Q1 24 | 2.34× | 2.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
WAT
暂无分部数据
